Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04961801 | Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Shin MineishiOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | withdrawn | Phase 2 | 0 | Shirish M GadgeelOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04448834 | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | withdrawn | Phase 2 | 0 | Dorothy Sipkins, MD, PhDOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT04856475 | Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer(NeraBrain) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 0 | Mar 2, 2022 | clinicaltrials |
| NCT03880279 | Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma(TACTIC-19) | withdrawn | Phase 1 / Phase 2 | 0 | Triumvira Immunologics, Inc.INDUSTRY | 0 | Feb 23, 2022 | clinicaltrials |
| NCT04179110 | Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT04832438 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | withdrawn | Phase 2 | 0 | Actuate Therapeutics Inc.INDUSTRY | 1 | Feb 22, 2022 | clinicaltrials |
| NCT03868423 | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | withdrawn | Phase 2 | 0 | Sameek RoychowdhuryOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Guru SonpavdeOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03321760 | SABR for T1-2a N1 NSCLC | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT04928950 | Charcoal in Lung Cancer Patients Undergoing TEMLA | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 9, 2022 | clinicaltrials |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 / Phase 3 | 0 | MacroGenicsINDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .(VERU-111) | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT03851081 | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | withdrawn | Phase 2 | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jan 24, 2022 | clinicaltrials |
| NCT04044209 | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT04607200 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | withdrawn | Phase 2 | 0 | Agenus Inc.INDUSTRY | 0 | Jan 11, 2022 | clinicaltrials |
| NCT04758949 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Jan 11, 2022 | clinicaltrials |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)(SOLUTION) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 10, 2022 | clinicaltrials |
| NCT04648826 | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2021 | clinicaltrials |
| NCT04672876 | Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 0 | Dec 17, 2021 | clinicaltrials |
| NCT03800784 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT04001101 | Anti-PD-1 +/- RT for MSI-H Solid Tumors | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT04038489 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer(Breast 51) | withdrawn | Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | withdrawn | Phase 2 | 0 | 4SC AGINDUSTRY | 0 | Nov 18, 2021 | clinicaltrials |
| NCT03661047 | OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer(OMICC) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04408898 | SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer | withdrawn | Phase 2 | 0 | AdaptimmuneINDUSTRY | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer | withdrawn | Phase 2 | 0 | Boehringer IngelheimINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT03943342 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | withdrawn | Phase 2 | 0 | Kerry RogersOTHER | 0 | Nov 5, 2021 | clinicaltrials |
| NCT04995094 | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | withdrawn | Phase 2 | 0 | HiberCell, Inc.INDUSTRY | 1 | Nov 5, 2021 | clinicaltrials |
| NCT05007769 | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC(RAN) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Nov 5, 2021 | clinicaltrials |
| NCT00006669 | Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | Medstar Health Research InstituteOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT01960023 | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | NSABP Foundation IncNETWORK | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04262869 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Oct 27, 2021 | clinicaltrials |
| NCT04430985 | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer(IMMUNOX) | withdrawn | Phase 2 | 0 | Dorte NielsenOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00003405 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | Rush University Medical CenterOTHER | 1 | Oct 14, 2021 | clinicaltrials |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | withdrawn | Phase 2 | 0 | Antonio FojoOTHER | 0 | Oct 13, 2021 | clinicaltrials |
| NCT04607642 | Trial of BMX-001 or Placebo in Head and Neck Cancer Patients | withdrawn | Phase 2 | 0 | BioMimetix JV, LLCINDUSTRY | 0 | Oct 11, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2022source: clinicaltrials